

Arjun V Balar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9071949/publications.pdf>

Version: 2024-02-01

20
papers

6,614
citations

687335

13
h-index

839512

18
g-index

21
all docs

21
docs citations

21
times ranked

8152
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
3	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017, 18, 1483-1492.	10.7	1,034
4	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	1.6	404
5	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	1.6	110
6	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
7	High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2019, 129, 146-152.	1.0	29
8	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	1.9	27
9	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	1.9	21
10	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	7.0	21
11	Atezolizumab in invasive and metastatic urothelial carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1295-1301.	3.1	20
12	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
13	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 24.	4.0	16
14	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
15	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019, 24, 688-690.	3.7	15
16	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983928.	2.0	13
17	Cytotoxic and DNA-targeted therapy in urothelial cancer: Have we squeezed the lemon enough?. <i>Cancer</i> , 2015, 121, 179-187.	4.1	12
18	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States. <i>JCO Oncology Practice</i> , 2022, 18, e620-e625.	2.9	3
20	Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment. <i>Bladder Cancer</i> , 2021, 7, 347-354.	0.4	2